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Abstract
C12H11N5, monoclinic, P21/n (no. 14), a= 7.3455(1) Å,
b= 12.2470(1) Å, c= 12.1689(1) Å, β= 103.505(1)°,
V = 1064.45(2) Å3, Z= 4, Rgt(F)=0.0365, wRref(F2)=0.0987,
T= 100 K.
CCDC no.: 1825596
The asymmetric unit of the title crystal structure is shown in
the figure. Tables 1 and 2 contain details on crystal structure
andmeasurement conditions and a list of the atoms including
atomic coordinates and displacement parameters.
Source of material
The compound was prepared and characterised as described
in the literature [5]. Crystals for the crystallographic study
were obtained from the slow evaporation of a very dilute
methanol solution.
Experimental details
The C-bound H atoms were geometrically placed (C—
H=0.98−0.99 Å) and refined as riding with U iso(H)= 1.2–
1.5Ueq(C). The N-bound hydrogen atoms were located in
difference Fourier maps, but were refined with a distance
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Table 1: Data collection and handling.
Crystal: Block, colourless
Size: 0.44×0.16×0.09 mm
Wavelength: Cu Kα radiation (1.54184 Å)
µ: 0.73 mm−1
Diffractometer, scan mode: SuperNova, φ and ω-scans
θmax, completeness: 76.5°,>99%
N(hkl)measured, N(hkl)unique, Rint: 18249, 2225, 0.026
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 2132
N(param)refined: 163
Programs: CrysAlisPRO [1], SHELX [2, 3],
WinGX and ORTEP [4]
restraint of N—H=0.88±0.01 Å, and with unconstrained
U iso(H).
Discussion
The 5-aza-7-deaza-isostere (imidazo[1,2-a][1, 3, 5]triazine) of
the purine system is an important scaffold for the construc-
tion of various drugs. Such compounds have been developed
as inhibitors for enzymes, e.g. focal adhesion kinase [6]. Fur-
ther, these compounds display anti-viral activity [7], are ago-
nists of opioid m-receptors [8] and function as ligands for
adenosine receptors [9]. A hindrance to the embellishment of
this class of compound has been the difficulty in their synthe-
sis. Very recently, a new procedure for the synthesis of 5-aza-7-
deaza-isosteres was developed, i.e. through the reaction of 2-
aminoimidazoles, triethylorthoformate and cyanamide under
microwave irradiation [5]. The title compound was one of the
new compounds synthesised in the course of that study.
The title molecule is shown in the figure (70% displace-
ment ellipsoids) and comprises a six- and five-membered
fused ring system connected to the 4-methylphenyl group at
C4. The r.m.s. deviation of the nine atoms of the imidazo-
triazine group is 0.0218 Åwith themaximumdeviationsbeing
0.0399(7) Å for the C2 atom and to the other side of the least-
squares plane, 0.0273(7) Å for the C3 atom. The amino-N5
atom lies 0.1258(13) Å out of the plane in the direction of the
C2 atom. There is a twist between this plane and that through
the appended 4-methylphenyl group as seen in the dihedral
angle of 12.39(4)° formed between them. The overall molecu-
lar geometry resembles that reported for the4-methoxyphenyl
derivative [5].
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Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom x y z Uiso*/Ueq
N1 0.65755(12) 0.76747(7) 0.76013(7) 0.0160(2)
N2 0.56271(12) 0.90789(7) 0.62085(7) 0.0152(2)
N3 0.43165(12) 0.73441(7) 0.58693(7) 0.0135(2)
N4 0.51177(12) 0.59379(7) 0.70583(7) 0.0153(2)
N5 0.35748(13) 0.86947(7) 0.44944(7) 0.0167(2)
H1N 0.2954(19) 0.8213(10) 0.4000(11) 0.027(4)*
H2N 0.382(2) 0.9366(8) 0.4286(12) 0.026(4)*
C1 0.65857(14) 0.86774(8) 0.72106(8) 0.0158(2)
H1 0.7367 0.9183 0.7696 0.019*
C2 0.45045(14) 0.83930(8) 0.55095(8) 0.0137(2)
C3 0.32629(14) 0.64623(8) 0.53665(8) 0.0145(2)
H3 0.2379 0.6448 0.4659 0.017*
C4 0.37712(14) 0.56166(8) 0.61100(8) 0.0143(2)
C5 0.54085(14) 0.69780(8) 0.68995(8) 0.0139(2)
C6 0.30889(14) 0.44836(8) 0.59856(8) 0.0147(2)
C7 0.20768(15) 0.40938(9) 0.49422(9) 0.0175(2)
H7 0.1760 0.4576 0.4315 0.021*
C8 0.15305(15) 0.30053(9) 0.48163(9) 0.0184(2)
H8 0.0847 0.2754 0.4100 0.022*
C9 0.19638(14) 0.22754(8) 0.57174(9) 0.0172(2)
C10 0.29339(15) 0.26757(8) 0.67647(9) 0.0186(2)
H10 0.3222 0.2196 0.7395 0.022*
C11 0.34874(15) 0.37631(8) 0.69031(9) 0.0172(2)
H11 0.4140 0.4018 0.7625 0.021*
C12 0.14124(16) 0.10914(9) 0.55662(9) 0.0212(2)
H12A 0.0357 0.0951 0.5912 0.032*
H12B 0.2476 0.0633 0.5930 0.032*
H12C 0.1045 0.0919 0.4758 0.032*
As anticipated, the molecular packing features a num-
ber of conventional hydrogen-bonding interactions. Thus,
centrosymmetricaly related molecules associate via amine-
N—H· · ·N(triazine) hydrogen bonds and eight-membered
{· · ·HNCN}2 synthons [N5—H2n· · ·N2: 2.066(11) Å and
179.6(17)° for symmetry operation 1−x, 2−y, 1−z]. The dimeric
aggregates are connected into twisted, one-dimensional
supramolecular chains, parallel to [1 0 1¯], via amine-
H· · · amine-N—H· · ·N(triazine) hydrogen bonds, involving
the other amine-H and triazine-N atoms [N5—H1n· · ·N1:
2.074(13) Å and 168.2(12)° for symmetry operation −1/2+ x,
3/2−y,−1/2+ z].
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